Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03132324 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03132324 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 12 participants.
The verdict
NCT03132324, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and tolerability, and the pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.
Interventions
- DRUG INCB059872
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03132324
The ClinicalTrials.gov registry entry for NCT03132324 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB059872 is the first listed.
NCT03132324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03132324 about?
NCT03132324 is a clinical study titled "A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease". The purpose of this study was to evaluate the safety and tolerability, and the pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.
What is the current status of trial NCT03132324?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-04-20. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT03132324?
The interventions under investigation include: INCB059872 (DRUG).
Who is sponsoring clinical trial NCT03132324?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.